Evaluation of barriers to cervical cancer screening in Georgia
Central European Journal of Public Health · 31.03.2023 · 31 (1) · 9-18
DOI: 10.21101/cejph.a7621 ↗Kurz gefasst
Fachartikel in der Zeitschrift Central European Journal of Public Health, erschienen am 31.03.2023. Verfasst von Gvantsa Guliashvili und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: The Cervical Cancer (CC) Screening Programme in Georgia provides insufficient coverage of the target population. The aim of the study is to identify the barriers to cervical cancer screening for women in Georgia in order to plan and implement adequate measures to increase the screening effectiveness. METHODS: The study is based on the results of a survey of 582 women aged 25-60 years (mean age 42.11 + 12.17). Respondents were selected in out-patient clinics. The questionnaire included questions related to the place of residence, ethnicity, religion, marital status, education, employment, cervical cancer awareness and screening, screening participation practices, and barriers to participation. RESULTS: The following factors reliably increase the chance of participating in the screening: residing in Tbilisi, OR = 1.84 (95% CI: 1.10-3.07); higher education, OR = 1.87 (95% CI: 1.09-3.19); being employed as a nurse, OR = 3.42 (95% CI: 1.49-7.85); receiving screening-related information from medical staff, OR = 2.43 (95% CI: 1.42-4.15); and from television, OR = 2.57 (95% CI: 1.47-4.50). The chance of participating in the screening is reduced due to incomplete secondary education, OR = 0.10 (95% CI: 0.01-0.77); single marital status, OR = 0.49 (95% CI: 0.28-0.87); employment in public service, OR = 0.39 (95% CI: 0.17-0.89); and receiving screening-related information from friends, OR = 0.26 (95% CI: 0.09-0.77). Women with higher education are undoubtedly more informed about screening, screening procedures and free programmes than those without higher education. The common barrier to participation in the screening was "fear of the manipulation-related pain" but the most frequent answer was "I'm afraid that the test will detect cancer (36.3%)." Women with a lower level of education are more likely to believe that "Pap testing is appropriate for the women who have active sexual life", and/or "have multiple sexual partners", and/or "have children," and "it is not necessary if a woman has no complaints". CONCLUSION: Screening participation among women in Georgia depends on screening availability, formal education and awareness of CC, sources of information, and employment type.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia.
- Georgian National Screening Centre, Tbilisi, Georgia.
- David Aghmashenebeli University of Georgia, Tbilisi, Georgia.
- National Centre for Disease Control and Public Health, Tbilisi, Georgia.
Zitieren
APA
Guliashvili, G., Taboridze, I., Mebonia, N., Alibegashvili, T., Kazakhashvili, N., & Imnadze, P. (2023). Evaluation of barriers to cervical cancer screening in Georgia. Central European Journal of Public Health, 31(1), 9-18. https://doi.org/10.21101/cejph.a7621
Vancouver
Guliashvili G, Taboridze I, Mebonia N, Alibegashvili T, Kazakhashvili N, Imnadze P. Evaluation of barriers to cervical cancer screening in Georgia. Central European Journal of Public Health. 2023;31(1):9-18. doi:10.21101/cejph.a7621
BibTeX
@article{Guliashvili2023,
author = {Guliashvili, Gvantsa and Taboridze, Iamze and Mebonia, Nana and Alibegashvili, Tamar and Kazakhashvili, Nata and Imnadze, Paata},
title = {Evaluation of barriers to cervical cancer screening in Georgia},
journal = {Central European Journal of Public Health},
year = {2023},
volume = {31},
number = {1},
pages = {9--18},
doi = {10.21101/cejph.a7621}
}
EUVIMED